This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sonia Anand, MD; Jeffrey S. Ginsberg, MD; Clive Kearon, MB; Michael Gent, DSc; Jack Hirsh, MD

Arch Intern Med. 1996;156(15):1677-1681.

Abstract
Background
It is unknown whether the true risk of recurrent venous thromboembolism (VTE) is increased in patients with proximal deep vein thrombosis who are treated with continuous intravenous heparin and fail to reach a therapeutic activated partial thromboplastin time (APTT) within 24 to 48 hours of initiation of treatment.

Methods
To compare the risk of recurrent VTE in patients with early subtherapeutic APTT results and those with APTT results above the lower limit of the therapeutic range, we performed a formal review of the literature. We examined all available studies that provided information on the relation between the risk of recurrent VTE and the APTT response to heparin when initiated as a bolus followed by a continuous intravenous infusion of at least 30 000 U/24 h.

Results
Five studies were included in the final analysis. The overall recurrence rate was 6.3% in patients whose APTT results were subtherapeutic for the first 24 to 48 hours and 7% in patients whose APTT results were above the lower limit of the therapeutic range, providing a pooled odds ratio of 0.89 with a 95% confidence interval of 0.2 to 4.0.

Conclusions
In patients with VTE who are treated with a bolus of heparin followed by a continuous intravenous infusion of at least 30 000 U/24 h, no convincing evidence shows that the risk of recurrent VTE is critically dependent on achieving a therapeutic APTT result at 24 to 48 hours.

Arch Intern Med. 1996;156:1677-1681

Author Affiliations
From the Departments of Medicine (Drs Anand, Ginsberg, Kearon, and Hirsh) and Clinical Epidemiology and Biostatistics (Dr Gent), McMaster University, Hamilton, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anticoagulant Therapy for Acute Venous Thromboembolism: What We Think We Know and What the Data Show for the Timing of Recurrent Events
Stein et al.
CLIN APPL THROMB HEMOST 2009;15:609-612.
ABSTRACT  

Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT | FULL TEXT  

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
Kearon et al.
JAMA 2006;296:935-942.
ABSTRACT | FULL TEXT  

Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost.
Carson
JAMA 2006;296:991-993.
FULL TEXT  

How I treat venous thromboembolism in patients with cancer
Prandoni
Blood 2005;106:4027-4033.
ABSTRACT | FULL TEXT  

Initial Treatment of Venous Thromboembolism
McRae and Ginsberg
Circulation 2004;110:I-3-I-9.
ABSTRACT | FULL TEXT  

Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism
Writing Committee for the Galilei Investigators
Arch Intern Med 2004;164:1077-1083.
ABSTRACT | FULL TEXT  

Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Hirsh et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21 :e9-e9.
FULL TEXT  

Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Hirsh et al.
Circulation 2001;103:2994-3018.
FULL TEXT  

Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective
Hirsh and Bates
ANN INTERN MED 2001;134:409-417.
ABSTRACT | FULL TEXT  

Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin
Bates et al.
Arch Intern Med 2001;161:385-391.
ABSTRACT | FULL TEXT  

Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Hirsh et al.
Chest 2001;119 :64S-94S.
FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers et al.
Chest 2001;119 :176S-193S.
FULL TEXT  

Recurrent Venous Thrombosis and Heparin Therapy: An Evaluation of the Importance of Early Activated Partial Thromboplastin Times
Anand et al.
Arch Intern Med 1999;159:2029-2032.
ABSTRACT | FULL TEXT  

Effect of Warfarin on Activated Partial Thromboplastin Time in Patients Receiving Heparin
Kearon et al.
Arch Intern Med 1998;158:1140-1143.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparin versus Unfractionated Heparin for Unstable Coronary Disease
Kearon et al.
NEJM 1998;338:129-131.
FULL TEXT  

Relation Between the Time to Achieve the Lower Limit of the APTT Therapeutic Range and Recurrent Venous Thromboembolism During Heparin Treatment for Deep Vein Thrombosis
Hull et al.
Arch Intern Med 1997;157:2562-2568.
ABSTRACT  

Effect of Weight, Sex, Age, Clinical Diagnosis, and Thromboplastin Reagent on Steady-state Intravenous Heparin Requirements
White et al.
Arch Intern Med 1997;157:2468-2472.
ABSTRACT  

Inability of the Activated Partial Thromboplastin Time to Predict Heparin Levels: Time to Reassess Guidelines for Heparin Assays
Baker et al.
Arch Intern Med 1997;157:2475-2479.
ABSTRACT  

The Importance of Initial Heparin Treatment on Long-term Clinical Outcomes of Antithrombotic Therapy: The Emerging Theme of Delayed Recurrence
Hull et al.
Arch Intern Med 1997;157:2317-2321.
ABSTRACT